Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för fruquintinib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

39 träffar

Bibliografisk träff 2022-11-04

A phase Ib/II study of fruquintinib in combination with paclitaxel as the second-line therapy for advanced gastric cancer.

Zhang Y, Wang ZX, Shen L, Li J, Huang J, Su WG, Zhang DS, Xu RH.

Cancer Commun (Lond) · letter; research support, non-u.s. gov't · DOI 10.1002/cac2.12379

Bibliografisk träff 2022-07-31

Pharmacokinetic study of deufruquintinibs in rats by HPLC-MS/MS after oral administration.

Hu J, Liu W, Wang Y, Chen X, Guo Y, Peng Q, Guo J, Zhang H, Zhang S, Deng G.

Biomed Chromatogr · journal article · DOI 10.1002/bmc.5459

Bibliografisk träff 2022-04-28

Combining Fruquintinib and Doxorubicin in Size-Converted Nano-Drug Carriers for Tumor Therapy.

Zhang N, Xin X, Feng N, Wu D, Zhang J, Yu T, Jiang Q, Gao M, Yang H, Zhao S, Tian Q, Zhang Z.

ACS Biomater Sci Eng · journal article · DOI 10.1021/acsbiomaterials.1c01606

Bibliografisk träff 2022-01-21

Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer.

Liu S, Lu L, Pan F, Yang C, Liang J, Liu J, Wang J, Shen R, Xin FZ, Zhang N.

Oncol Res · research-article; journal article · DOI 10.3727/096504022x16427607626672

Bibliografisk träff 2022-01-20

Efficacy and Safety Comparison of Regorafenib and Fruquintinib in Metastatic Colorectal Cancer-An Observational Cohort Study in the Real World.

Zhang Q, Chen M, Wang Z, Qi C, Cao Y, Zhang J, Peng Z, Wang X, Lu M, Shen L, Li J.

Clin Colorectal Cancer · research support, non-u.s. gov't; journal article; observational study · DOI 10.1016/j.clcc.2022.01.007

Bibliografisk träff 2021-06-02

Effects of Fruquintinib on the Pluripotency Maintenance and Differentiation Potential of Mouse Embryonic Stem Cells.

Zeng H, Peng F, Wang J, Meng R, Zhang J.

Cell Reprogram · research support, non-u.s. gov't; journal article · DOI 10.1089/cell.2020.0100

Bibliografisk träff 2021-05-17

FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer.

Dasari A, Sobrero A, Yao J, Yoshino T, Schelman W, Yang Z, Chien C, Kania M, Tabernero J, Eng C.

Future Oncol · clinical trial protocol; journal article · DOI 10.2217/fon-2021-0202

Bibliografisk träff 2021-05-17

Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study.

Jiang FE, Zhang HJ, Yu CY, Liu AN.

Neoplasma · journal article; observational study · DOI 10.4149/neo_2021_201228n1415

Bibliografisk träff 2020-11-27

Fruquintinib inhibits VEGF/VEGFR2 axis of choroidal endothelial cells and M1-type macrophages to protect against mouse laser-induced choroidal neovascularization.

Liu X, Guo A, Tu Y, Li W, Li L, Liu W, Ju Y, Zhou Y, Sang A, Zhu M.

Cell Death Dis · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41419-020-03222-1